Lilly-backed in vivo CAR-T delivers durable MRD-negativity in multiple myeloma

Kelonia Therapeutics’ KLN-1010, an off-the-shelf in vivo CAR-T for BCMA in relapsed/refractory multiple myeloma, produced MRD-negativity in all 18 treated patients at one month, with all assessable patients remaining MRD-negative at six months and the longest follow-up over 10 months. The safety profile is favorable (mostly grade 1–2 CRS and two ICANS cases). Lilly’s $3.2 billion deal for Kelonia could accelerate moving KLN-1010 into earlier lines and set the stage for phase 3 trials and broader in vivo CAR-T applications across cancer types.